Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vertex Pharmaceuticals (DE:VX1)
XETRA:VX1
RESEARCH TOOLSreports
Holding DE:VX1?
Track your performance easily
VX1 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€310.00 - €455.00
Previous Close€453.15
Volume21.00
Average Volume (3M)522.00
Market Cap
€115.81B
Enterprise Value€107.13B
Total Cash (Recent Filing)$10.17B
Total Debt (Recent Filing)$721.30M
Price to Earnings (P/E)31.9
Beta0.02
Next Earnings
Aug 01, 2024EPS Estimate
€3.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)14.22
Shares Outstanding258,053,387
10 Day Avg. Volume105
30 Day Avg. Volume522
Standard Deviation0.07
R-Squared0.00188
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)6.08
Price to Sales (P/S)11.42
Price to Cash Flow (P/CF)23.10
P/FCF Ratio28.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue10.52
Enterprise Value/Gross Profit12.45
Enterprise Value/Ebitda28.30
Forecast
1Y Price Target
€432.39Price Target Upside-4.34% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering22
Vertex Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ExpansionVertex has expanded the phase 1/2 FORWARD trial to enroll 37 patients, underscoring management’s confidence in their burgeoning T1D franchise.
Clinical Trial ResultsAll patients treated with VX-880 at the latest visit were found to have improved glycemic control and had both HbA1c < 7.0% and time-in-range above 70% (70-180 mg/dL) based on continuous glucose monitoring.
Patient OutcomesAmong the 10 patients that completed the Day 180 visit, seven are insulin independent.
Bears Say
Commercial OpportunityThe commercial opportunity for VX-880 may be limited given the current requirement for patients to remain on immunosuppressives.
Growth DriversIt is unclear whether povetacicept may be the next major growth driver for Vertex to build on its mature cystic fibrosis (CF) franchise.
ValuationVertex shares trade at a significant premium to the peer average, making the stock less attractive compared to its competitors.
---
Options Prices
Currently, No data available
---
Ownership Overview
1.04% Insiders
53.51% Mutual Funds
23.27% Other Institutional Investors
22.18% Public Companies and
Individual Investors
VX1 FAQ
What was Vertex Pharmaceuticals’s price range in the past 12 months?
Vertex Pharmaceuticals lowest stock price was €310.00 and its highest was €455.00 in the past 12 months.
What is Vertex Pharmaceuticals’s market cap?
Currently, no data Available
When is Vertex Pharmaceuticals’s upcoming earnings report date?
Vertex Pharmaceuticals’s upcoming earnings report date is Aug 01, 2024 which is 79 days ago.
How were Vertex Pharmaceuticals’s earnings last quarter?
Vertex Pharmaceuticals released its earnings results on May 06, 2024. The company reported €4.37 earnings per share for the quarter, beating the consensus estimate of €3.739 by €0.631.
Is Vertex Pharmaceuticals overvalued?
According to Wall Street analysts Vertex Pharmaceuticals’s price is currently Overvalued.
Does Vertex Pharmaceuticals pay dividends?
Vertex Pharmaceuticals does not currently pay dividends.
What is Vertex Pharmaceuticals’s EPS estimate?
Vertex Pharmaceuticals’s EPS estimate is €3.82.
How many shares outstanding does Vertex Pharmaceuticals have?
Vertex Pharmaceuticals has 258,053,380 shares outstanding.
What happened to Vertex Pharmaceuticals’s price movement after its last earnings report?
Vertex Pharmaceuticals reported an EPS of €4.37 in its last earnings report, beating expectations of €3.739. Following the earnings report the stock price went up 2.595%.
Which hedge fund is a major shareholder of Vertex Pharmaceuticals?
Among the largest hedge funds holding Vertex Pharmaceuticals’s share is Antipodes Partners Ltd. It holds Vertex Pharmaceuticals’s shares valued at 79M.
---
Vertex Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€432.39 (-4.34% Downside)
€432.39 (-4.34% Downside)
Blogger Sentiment
Bullish
DE:VX1 Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
41.22%
12-Months-Change
Fundamentals
Return on Equity
24.38%
Trailing 12-Months
Asset Growth
26.05%
Trailing 12-Months
Company Description
Vertex Pharmaceuticals
Based in Massachusetts and incorporated in 1989, Vertex Pharmaceuticals, Inc. is a biopharmaceutical company, which is engaged in the development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
---
VX1 Company Deck
---
VX1 Earnings Call
Q1 2024
0:00 / 0:00
---
VX1 Revenue Breakdown
90.63% TRIKAFTA/KAFTRIO
4.82% KALYDECO
3.30% ORKAMBI
1.25% SYMDEKO/SYMKEVI
---
VX1 Stock 12 Month Forecast
Average Price Target
€432.39
▼(-4.34% Downside)
Technical Analysis
Vertex Pharmaceuticals
―
Agios Pharma
―
Alnylam Pharma
―
Bluebird Bio
―
Crispr Therapeutics AG
―
Best Analysts Covering VX1
1 Year
1 Year Success Rate
12/12 ratings generated profit
1 Year Average Return
+27.01%
assigned a buy rating 6 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +27.01% per trade.
---